Insilico Medicine (03696) saw its shares climb more than 9% during early trading. By the time of writing, the stock had increased by 3.98%, reaching HK$61.40, with a turnover of HK$242 million.

On April 8, Insilico Medicine announced the nomination of ISM6200, a potent and potentially best-in-class NR3C1 inhibitor, as a preclinical candidate compound (PCC). The compound is intended for the treatment of ovarian cancer, Cushing's syndrome, and other conditions associated with elevated cortisol levels, including glucocorticoid-related obesity.

Public information indicates that ISM6200 is a potent and selective NR3C1 antagonist developed using Insilico Medicine's Pharma.AI platform. It carries a low risk of drug-drug interactions (DDI) and has demonstrated superior efficacy in various animal disease models. The compound also exhibits favorable ADME/PK properties, with a predicted low effective dose in humans, suggesting best-in-class potential.

It is noteworthy that at the end of March, Insilico Medicine announced a collaboration with Eli Lilly involving an agreement worth up to approximately $2.75 billion. The deal includes an upfront payment of $115 million. According to the announcement, the partnership not only covers the licensing of a preclinical pipeline but also entails multiple drug development collaborations on selected targets, supported by Insilico Medicine's Pharma.AI platform. Pharma.AI is a commercial generative artificial intelligence software and automation platform developed by Insilico Medicine specifically to enhance the quality and efficiency of pharmaceutical research and development.